肾移植后抗肾小球基底膜肾小球肾炎的复发与结局
这项多中心回顾性研究纳入1977至2015年间接受肾移植的53例抗GBM肾小球肾炎患者,评估移植后复发风险及长期生存。仅1例在首次移植后5年因停用免疫抑制剂而复发(患病率1.9%),并导致移植物丢失。患者5、10、15年生存率分别为100%、94%、89%,死亡删失的首次移植物生存率分别为88%、83%、79%。
要点
- 抗GBM病肾移植后临床复发罕见,患病率1.9%。
- 复发多与停用免疫抑制剂相关,可导致移植物丢失。
- 长期患者及移植物存活率优良。
核心结论
- 肾移植后抗GBM肾小球肾炎复发率极低,但复发与移植物丢失相关。
- 长期患者和移植物生存率优良。
研究设计与样本
- 多中心回顾性研究,纳入1977至2015年间接受肾移植的抗GBM肾小球肾炎患者53例。
- 排除系统性血管炎、狼疮 erythematosus 和冷球蛋白血症。
主要发现
- 首次肾移植后仅1例在移植后5年复发,患病率1.9%,发生在停用免疫抑制剂背景下,并因复发导致移植物丢失。
- 4例患者肾活检显示线性IgG沉积但无增殖性肾小球肾炎组织学征象,见于细胞性排斥反应背景下。
- 患者5年、10年、15年生存率分别为100%、94%、89%。
- 死亡删失的首次移植物5年、10年、15年生存率分别为88%、83%、79%。
关键数值与推荐
- 复发定义为临床肾小球肾炎征象再现,伴肾活检增殖性肾小球肾炎组织学征象和线性IgG沉积,伴或不伴抗GBM抗体。
临床怎么用
- 肾移植后抗GBM病复发风险低,但仍需警惕,尤其当免疫抑制减弱时。
- 维持适当免疫抑制可能有助于预防复发。
局限性
- 回顾性研究设计。
- 样本量较小(53例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis in the kidney graft is a rare event, described in limited reports. The aim of this study was to evaluate, in a large cohort of patients with long follow-up, the risk of recurrence of anti-GBM disease, the risk factors associated with clinical recurrence, and the long-term patient and graft survival. METHODS: This was a multicenter retrospective study. Inclusion criteria were patients with anti-GBM glomerulonephritis who underwent transplantation of a kidney between 1977 and 2015. Exclusion criteria were systemic vasculitis, lupus erythematosus, and cryoglobulinemia. Recurrence was defined as reappearance of clinical signs of glomerulonephritis along with histological signs of proliferative glomerulonephritis and linear IgG staining on kidney biopsy, with or without anti-GBM antibodies. RESULTS: A total of 53 patients were included. Recurrence of anti-GBM glomerulonephritis in a first kidney transplant occurred in only 1 patient 5 years after transplantation (a prevalence rate of 1.9%) in the context of cessation of immunosuppressive drugs, and resulted in graft loss due to recurrence. Linear IgG staining on kidney biopsy in the absence of histological signs of proliferative glomerulonephritis was observed in 4 patients, in the context of cellular rejection. Patient survival was 100%, 94%, and 89% at 5, 10, and 15 years, respectively. Death-censored first-graft survival rates were 88%, 83%, and 79% at 5, 10, and 15 years, respectively. CONCLUSION: The recurrence rate of anti-GBM glomerulonephritis after transplantation is very low but is associated with graft loss. The long-term patient and graft survival rates are excellent.
引用
- Coche S, Sprangers B, Van Laecke S, et al. Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation. Kidney Int Rep. 2021. PMID: 34307983. doi:10.1016/j.ekir.2021.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。